Loading clinical trials...

Short-term Oral Prednisone for Acute Subjective Tinnitus | Clinical Trials | Clareo Health

COMPLETEDNA

Short-term Oral Prednisone for Acute Subjective Tinnitus

Investigating the Efficacy of Short-term Oral Prednisone Therapy on Acute Subjective Tinnitus

NCT05591144•Eye & ENT Hospital of Fudan University

Summary

The goal of this clinical trial is to investigate the efficacy of oral steroids in the acute tinnitus population. Participants will receive appropriate dosages of short-term prednisone and/or oral Ginkgo Biloba tablets.

Detailed Description

Researchers will compare the intervention group and placebo-control group to see whether short-term systemic steroid therapy is effective for acute tinnitus.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. 18-65 years old;
•2. a primary complaint of frequent occurrences of subjective tinnitus lasting at least 5 minutes within the past 3 months ;
•3. a definition of normal hearing in line with the World Report on Hearing (2021), of which the average value of hearing threshold at 500, 1000, 2000, 4000 Hz in better ear was less than 20 decibels;
•4. a score of more than 16 points on the Tinnitus Handicap Inventory (THI), which indicates that the level of tinnitus exceeds mild severity;
•5. a state of good general condition.

Exclusion Criteria

•1. had previous history of middle ear pathology, apparent history of noise exposure, noise trauma or head injury;
•2. had received treatment for their current condition before the study;
•3. taken oral steroids within 3 months before randomization;
•4. had hearing implants;
•5. had participated in other clinical trials and have not terminated the trials;
•6. had a history of known corticosteroid contraindications (including osteoporosis, peptic ulcers, poorly controlled hypertension, diabetes, chronic liver or renal insufficiency, tumorous condition, alcohol abuse, pregnancy, or taking estrogen-containing oral contraceptive steroids);
•7. auditory hallucinations or other conditions deemed inappropriate for inclusion by the investigator.

Locations (1)

Eye and ENT Hospital of Fudan University

Shanghai, China

Key Dates

Start Date

October 30, 2022

Primary Completion Date

January 22, 2023

Completion Date

February 3, 2024

Last Updated

February 28, 2025

Enrollment

146

ACTUAL participants

Conditions

Tinnitus, Subjective

Interventions

Prednisone tablet

DRUG

Ginkgo Biloba Extract

DRUG

Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus

NCT07393880

Tinnitus, SubjectiveTinnitus+1 more

View study

RECRUITINGNA

Noninvasive Therapy for Tinnitus

NCT07071480

TinnitusTinnitus, Subjective

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Short-term Oral Prednisone for Acute Subjective Tinnitus

Inclusion Criteria

Exclusion Criteria

Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus

Noninvasive Therapy for Tinnitus

Multimodal Therapy for Somatosensory Tinnitus

Broadband Amplification as Tinnitus Treatment

Evaluating the GN ReSound Relief App Using task-and Rest-based fMRI

Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors